Literature DB >> 21232805

Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

Stefan Löber1, Harald Hübner, Nuska Tschammer, Peter Gmeiner.   

Abstract

Dopamine D(2)-like receptors (including D(2), D(3) and D(4)) belong to the 'rhodopsin-like' family of G protein-coupled receptors (GPCRs), which represent the largest group of targets for bioactive molecules. Due to their high sequence similarity, the design of subtype-selective ligands requires rational and effective strategies. The general formula of 1,4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) was extracted from classical dopaminergic drugs. The biological properties of this compound family are encoded by an aromatic head group that controls intrinsic activity, an amine moiety and a lipophilic appendage. D(3)- and D(4)-selective molecular probes and drug candidates were generated from the general formula of 1,4-DAP. Formal structural rearrangement led to investigational drugs beyond the 1,4-DAP structure. The very recent publication of the X-ray crystal structure of D(3) should facilitate efficient discovery of unprecedented chemotypes. However, the development of D(3)-selective agonists, functionally selective ligands and the exploitation of homo- and heteromers remain challenging.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232805     DOI: 10.1016/j.tips.2010.12.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  34 in total

1.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

2.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

3.  Multicomponent Synthesis and Biological Evaluation of a Piperazine-Based Dopamine Receptor Ligand Library.

Authors:  Mattia Stucchi; Peter Gmeiner; Harald Huebner; Giulia Rainoldi; Alessandro Sacchetti; Alessandra Silvani; Giordano Lesma
Journal:  ACS Med Chem Lett       Date:  2015-06-23       Impact factor: 4.345

4.  Persistence of associations between cognitive impairment and motor dysfunction in the early phase of Parkinson's disease.

Authors:  Magdalena E Domellöf; Lars Forsgren; Eva Elgh
Journal:  J Neurol       Date:  2013-05-29       Impact factor: 4.849

5.  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Authors:  Anne Stößel; Regine Brox; Nirupam Purkayastha; Harald Hübner; Carsten Hocke; Olaf Prante; Peter Gmeiner
Journal:  Bioorg Med Chem       Date:  2017-04-29       Impact factor: 3.641

6.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

7.  Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.

Authors:  Cheryse A Furman; Rebecca A Roof; Amy E Moritz; Brittney N Miller; Trevor B Doyle; R Benjamin Free; Ashwini K Banala; Noel M Paul; Vivek Kumar; Christopher D Sibley; Amy Hauck Newman; David R Sibley
Journal:  Eur Neuropsychopharmacol       Date:  2014-11-29       Impact factor: 4.600

8.  A new era of rationally designed antipsychotics.

Authors:  David R Sibley; Lei Shi
Journal:  Nature       Date:  2018-03-08       Impact factor: 49.962

9.  Dopaminergic modulation of reward discounting in healthy rats: a systematic review and meta-analysis.

Authors:  Jaime J Castrellon; James Meade; Lucy Greenwald; Katlyn Hurst; Gregory R Samanez-Larkin
Journal:  Psychopharmacology (Berl)       Date:  2020-11-19       Impact factor: 4.530

10.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.

Authors:  Yongkai Cao; Ningning Sun; Jiumei Zhang; Zhiguo Liu; Yi-Zhe Tang; Zhengzhi Wu; Kyeong-Man Kim; Seung Hoon Cheon
Journal:  Medchemcomm       Date:  2018-06-14       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.